Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADILNASDAQ:AEONNASDAQ:FRTXOTCMKTS:NSPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$0.59+3.3%$0.68$0.51▼$3.00$4.69M1.181.10 million shs189,831 shsAEONAEON Biopharma$0.94+7.7%$0.51$0.38▼$269.28$10.63M0.571.01 million shs467,429 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsNSPXInspyr Therapeutics$0.00$0.00▼$0.07$1.47M-17.3313.19 million shs29.64 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals+3.34%-10.00%-2.53%-13.54%-54.66%AEONAEON Biopharma+7.71%+59.43%+98.56%+44.79%-99.13%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%-1.58%NSPXInspyr Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial Pharmaceuticals2.8074 of 5 stars3.83.00.00.02.70.01.3AEONAEON Biopharma3.348 of 5 stars3.55.00.00.00.61.71.9FRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANSPXInspyr TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial Pharmaceuticals 3.50Strong Buy$8.001,246.80% UpsideAEONAEON Biopharma 3.00Buy$360.0038,197.87% UpsideFRTXFresh Tracks Therapeutics 0.00N/AN/AN/ANSPXInspyr Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$2.46 per shareN/AAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/AFRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56NSPXInspyr TherapeuticsN/AN/AN/AN/A($0.07) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$5.12M-$1.46N/AN/AN/AN/A-168.25%-148.46%8/12/2025 (Estimated)AEONAEON Biopharma-$36.63M$298.125.22N/AN/AN/AN/A-994.63%8/11/2025 (Estimated)FRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/ANSPXInspyr Therapeutics-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/ALatest NSPX, FRTX, ADIL, and AEON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ADILAdial Pharmaceuticals-$0.50-$0.34+$0.16-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/AAEONAEON BiopharmaN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/ANSPXInspyr TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A6.786.78AEONAEON BiopharmaN/A0.220.22FRTXFresh Tracks TherapeuticsN/AN/AN/ANSPXInspyr TherapeuticsN/A0.090.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%AEONAEON Biopharma22.78%FRTXFresh Tracks Therapeutics25.04%NSPXInspyr Therapeutics0.02%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals5.24%AEONAEON Biopharma0.86%FRTXFresh Tracks Therapeutics0.23%NSPXInspyr Therapeutics0.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals207.90 million6.07 millionNo DataAEONAEON Biopharma511.31 million74.37 millionNot OptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableNSPXInspyr Therapeutics1543.15 millionN/ANot OptionableNSPX, FRTX, ADIL, and AEON HeadlinesRecent News About These CompaniesInspyr Supports Breast Cancer Survivors with 'More Than Just a Pink Ribbon' EventOctober 1, 2024 | msn.comEWTX Edgewise Therapeutics, Inc.April 4, 2024 | seekingalpha.comFAST joins with University of Pennsylvania to develop investigational AAV gene therapy for Angelman syndromeOctober 18, 2023 | news-medical.netMemo Therapeutics gets US FDA fast track designation for AntiBKV as treatment of BKV infection in renal transplant patientsMay 5, 2023 | pharmabiz.comDecibel Therapeutics gets European orphan drug designation for lead gene therapy candidate DB-OTOApril 3, 2023 | pharmabiz.comBrainStorm Cell Therapeutics announces US FDA committee to review BLA for NurOwn to treat amyotrophic lateral sclerosisMarch 29, 2023 | pharmabiz.comKuria Therapeutics completes US FDA pre-IND consultation for topical Nrf2 activator for corneal endothelial diseaseMarch 22, 2023 | pharmabiz.comCombined Therapeutics’ mRNA vaccine platform receives US patentMarch 16, 2023 | pharmabiz.comTG Therapeutics Stock (NASDAQ:TGTX), Analyst Ratings, Price Targets, PredictionsMarch 4, 2023 | benzinga.comInspyr Therapeutics Announces New Holding Company Structure and Reverse Stock SplitOctober 12, 2021 | ca.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNSPX, FRTX, ADIL, and AEON Company DescriptionsAdial Pharmaceuticals NASDAQ:ADIL$0.59 +0.02 (+3.34%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$0.59 0.00 (-0.17%) As of 06/10/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.AEON Biopharma NASDAQ:AEON$0.94 +0.07 (+7.71%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$0.92 -0.02 (-1.70%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.Inspyr Therapeutics OTCMKTS:NSPXInspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Hits All-Time Highs: Smart Buy or FOMO Trap? These 3 Stocks Could Be Back in Play Before You Know It Casey’s Surges on Strong Q4, More Gains Likely Ahead Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects Government Mandate Sends eVTOL Stocks Flying AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
